Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.

TRANSFUSION MEDICINE Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin

Whereas bleeding is the most frequent adverse event encountered in patients receiving glycoprotein (GP) IIb/IIIa inhibitors, there are currently no recommendations for how to treat such patients. The present study tested the hypothesis that infusion of desmopressin (DDAVP) reverses the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors ( L-aspirin). Study group 1 (10 healthy volunte...

DESMOPRESSIN AND PLATELETS ANTAGONIZE THE IN VITRO PLATELET DYSFUNCTION INDUCED BY GPIIb/IIIa INHIBITORS AND ASPIRIN

The platelet in diabetes: focus on prevention of ischemic events.

Accelerated atherosclerosis and the increased risk of thrombotic vascular events in diabetes may result from dyslipidemia, endothelial dysfunction, platelet hyperreactivity, an impaired fibrinolytic balance, and abnormal blood flow. There is also a correlation between hyperglycemia and cardiovascular (CV) events. The importance of platelets in the atherothrombotic process has led to investigati...

Thoughts evoked by MATCH and other trials.

Are Two “Antiplatelet” Drugs Better Than One? Many different processes are involved in platelet activation. Most drugs affect one of these chemical reactions. Theoretically, platelet functions (secretion, aggregation, and adhesion) can be reduced most effectively by using 1 agent or by inhibiting the final step in the attachment of the platelet to fibrin at the level of the glycoprotein IIb/III...

8th Seah Cheng Siang Memorial Lecture: new antithrombotic agents.

For the long-term prevention of thromboembolic events in patients with atherosclerotic vascular disease, aspirin is the preferred antiplatelet drug. Only clopidogrel was shown to be more effective and at least as safe than medium-dose aspirin in direct comparative large-scale trials. Aspirin inhibits the cyclooxygenase dependent pathway of platelet aggregation while ticlopidine and clopidogrel ...